Anti-amyloid drugs

Anti-amyloid drugs, also known as anti-amyloid antibodies (AAA),[1] are a class of monoclonal antibodies developed to treat Alzheimer's disease. The first drug in the class to be developed, in the early 2000s, is bapineuzumab, but it did not show effectiveness in later-stage trials.[2] The first drug to be approved by the US Food and Drug Administration (FDA) is aducanumab—in 2021.[3]

  1. ^ Gandy S (2023). "News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023". Molecular Neurodegeneration. 18 (1): 66. doi:10.1186/s13024-023-00656-x. PMC 10518943. PMID 37749530.
  2. ^ Cite error: The named reference Statement was invoked but never defined (see the help page).
  3. ^ Brockmann R, Nixon J, Love BL, Yunusa I (1 March 2023). "Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development". Viewpoint. Lancet Regional Health - Americas. 20: 100467. doi:10.1016/j.lana.2023.100467. PMC 9996432. PMID 36908502.